Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 10mg | $53.00$31.80 | $3.18/mg | In stock | Jul 8 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| IPCJ052609201 | May 2026 | — | Janoshik Analytical | Endotoxin | Unverified | View |
| IPA05261110K | May 2026 | 99.8% | Janoshik Analytical | Endotoxin |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. Ipamorelin is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Verified Peptides sell Ipamorelin?
Yes — Verified Peptides currently lists Ipamorelin in 1 variant starting at $31.80 ($3.18/mg).
Is Verified Peptides's Ipamorelin third-party tested?
Yes — Disclosed Labs has indexed 20 Certificates of Analysis for Verified Peptides's Ipamorelin, with the most recent showing 99.8% purity. Verified Peptides holds an overall trust grade of C (79/100) across all 364 COAs on file.
What is Verified Peptides's trust grade for Ipamorelin?
Verified Peptides has an overall Disclosed Labs trust grade of C (79/100), computed from 364 COAs across all peptides. The most recent Ipamorelin COA was issued by Janoshik Analytical.
Where is the cheapest Ipamorelin?
As of the latest data, Peptide Supply Co. offers Ipamorelin at $2.70/mg — compare with Verified Peptides's listing at $3.18/mg. See the full Ipamorelin price comparison.
Is Ipamorelin legal to buy?
Ipamorelin is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| Unverified |
| View |
| 01-26-0910I | Dec 2025 | 99.6% | Janoshik Analytical | Endotoxin | Unverified | View |
| 10-25-0720G | Oct 2025 | — | Janoshik Analytical | — | Unverified | View |
| 10-25-0810H | Sep 2025 | 99.7% | Janoshik Analytical | — | Unverified | View |
| — | Sep 2025 | 99.9% | Janoshik Analytical | — | Unverified | View |
| 08-25-0710G | Jul 2025 | 99.8% | Janoshik Analytical | — | Unverified | View |
| 03-25-0710G | Jun 2025 | 99.0% | Janoshik Analytical | Endotoxin | Unverified | View |
| 03-25-05056 | Mar 2025 | — | Janoshik Analytical | Endotoxin | Confirmed | View |
| — | Feb 2025 | 99.7% | Janoshik Analytical | — | Unverified | View |
| 09-24-0405E | Feb 2025 | — | Janoshik Analytical | Endotoxin | Confirmed | View |
| 09-24-0405D | Oct 2024 | — | Janoshik Analytical | Endotoxin | Unverified | View |
| — | Sep 2024 | 99.6% | Janoshik Analytical | — | Unverified | View |
| 07-24-0505E | Sep 2024 | 99.6% | Janoshik Analytical | Endotoxin | Unverified | View |
| 06-24-0305C | Jul 2024 | — | Janoshik Analytical | Endotoxin | Unverified1 flag | View |
| 05-24-0405D | May 2024 | 99.9% | Janoshik Analytical | — | Unverified | View |
| 42268C | Sep 2023 | 99.9% | Janoshik Analytical | — | Unverified | View |
| 654928 | Oct 2022 | 99.9% | Janoshik Analytical | Endotoxin | Unverified | View |
| 65492B | Mar 2021 | 98.9% | Janoshik Analytical | — | Unverified | View |
| 12382A | Jun 2020 | 99.5% | Janoshik Analytical | — | Unverified | View |